A review of the potential effect of vitamin D as an anti-inflammatory agent in cardiometabolic diseases DOI Creative Commons
Kabelo Mokgalaboni

Metabolism Open, Год журнала: 2025, Номер 25, С. 100348 - 100348

Опубликована: Янв. 9, 2025

The prevalence of cardiometabolic diseases is rising, and this fuelled by inflammation, which tends to be worse in individuals with vitamin D (VD) deficiency. While non-steroidal anti-inflammatory interventions are available, they present coagulation events. Hence, alternative therapy the form VD supplements gaining research interest. This study reviewed effect supplementation on focusing nuclear factor kappa-beta (NF-κβ), tumour necrosis factor-alpha (TNF-α) monocyte chemoattractant protein-1 (MCP-1) across different disease. Thirty-seven studies, 16 rodent models 21 clinical studies were evaluated. considered evidence from understand these markers inflammation its translatability studies. potential benefits notable rodents, effects less consistent Notably, showed a more pronounced impact reducing NF-κβ TNF-α; however, trials reported conflicting findings. Furthermore, was important MCP-1 models; partially demonstrated trials. Based findings, modulates disease inhibiting activation suppressing production TNF-α MCP-1. Although has some possible models, findings limited. presented calls for further randomised controlled assess patients living conditions as curb risk thereof. Future should also focus exploring dose-response, optimal dose, duration intervention among that may offer inflammation.

Язык: Английский

A review of the potential effect of vitamin D as an anti-inflammatory agent in cardiometabolic diseases DOI Creative Commons
Kabelo Mokgalaboni

Metabolism Open, Год журнала: 2025, Номер 25, С. 100348 - 100348

Опубликована: Янв. 9, 2025

The prevalence of cardiometabolic diseases is rising, and this fuelled by inflammation, which tends to be worse in individuals with vitamin D (VD) deficiency. While non-steroidal anti-inflammatory interventions are available, they present coagulation events. Hence, alternative therapy the form VD supplements gaining research interest. This study reviewed effect supplementation on focusing nuclear factor kappa-beta (NF-κβ), tumour necrosis factor-alpha (TNF-α) monocyte chemoattractant protein-1 (MCP-1) across different disease. Thirty-seven studies, 16 rodent models 21 clinical studies were evaluated. considered evidence from understand these markers inflammation its translatability studies. potential benefits notable rodents, effects less consistent Notably, showed a more pronounced impact reducing NF-κβ TNF-α; however, trials reported conflicting findings. Furthermore, was important MCP-1 models; partially demonstrated trials. Based findings, modulates disease inhibiting activation suppressing production TNF-α MCP-1. Although has some possible models, findings limited. presented calls for further randomised controlled assess patients living conditions as curb risk thereof. Future should also focus exploring dose-response, optimal dose, duration intervention among that may offer inflammation.

Язык: Английский

Процитировано

1